Depomed licenses Acuform drug delivery technology to Boehringer
As per the terms of the agreement, Boehringer Ingelheim has taken responsibility to develop and commercialize the products and it will pay a sum of $12.5m license fee
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
The study result suggested that INC42 has reduced spleen size in patients with primary myelofibrosis (MF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF), when compared with